Cerevance
Focus: Cerevance is a Boston-based biotech focused on CNS small molecules, with a publicly traded status and a commercial-stage asset (DAXXIFY) now at peak revenue. The company operates as a mid-cap biotech with neurology as its primary therapeutic focus.
Profile data last refreshed 16h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Total Funding
$5M
Open Jobs
0
About Cerevance
AI assessmentNot HiringNo open roles listed right now. Follow Cerevance to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Cerevance's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Mid-stage
1 Phase 3+
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Key Products
Peak
Approved BLA product now at peak commercial stage; primary revenue driver and proof of commercial execution in the aesthetic/neurology space.
Products & Portfolio (1)
Help build intelligence for Cerevance
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.